Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing.

Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing.

BRAF inhibitors have demonstrated improvement of overall survival in patients with metastatic melanoma and BRAF(V600) mutations. In order to evaluate BRAF tumor heterogeneity between primary and metastatic site, we have evaluated the performance of immunohistochemistry (IHC) with an anti-BRAF(V600E)...

Full description

Bibliographic Details
Main Authors: Lucile Boursault, Véronique Haddad, Béatrice Vergier, David Cappellen, Severine Verdon, Jean-Pierre Bellocq, Thomas Jouary, Jean-Philippe Merlio
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23976959/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23976959/?tool=EBI

Similar Items